Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04250883
Other study ID # NL72780.091.20
Secondary ID 2020-000411-79
Status Completed
Phase N/A
First received
Last updated
Start date December 24, 2020
Est. completion date March 7, 2022

Study information

Verified date April 2022
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intra-abdominal pressure (IAP) needed to create sufficient workspace during laparoscopic surgery affects the surrounding organs with ischemia-reperfusion injury and a systemic immune response. This effect is related to postoperative recovery, pain scores, opioid consumption, bowel function recovery, morbidity and possibly mortality. In clinical practice standard pressures of 12-16mmHg are applied instead of the lowest possible IAP, but accumulating evidence shows lower pressure pneumoperitoneum (PNP) (6-8mmHg) to be non-compromising for sufficient workspace, when combined with deep neuromuscular blockade (NMB) in a vast majority of patients. Therefore, low impact laparoscopy, meaning low pressure PNP facilitated by deep NMB, could be a valuable addition to Enhanced Recovery After Surgery (ERAS) Protocols. The use of low pressure PNP may also reduce hypoxic injury and the release of DAMPs and thereby contributing to a better preservation of innate immune function which may help to reduce the risk of infectious complications. The participants will be randomly assigned to one of the experimental groups with low impact laparoscopy or one of the control groups with standard laparoscopy.


Description:

Intra-abdominal pressure (IAP) needed to create sufficient workspace during laparoscopic surgery affects the surrounding organs with ischemia-reperfusion injury and a systemic immune response. This effect is related to postoperative recovery, pain scores, opioid consumption, bowel function recovery, morbidity and possibly mortality. Therefore, low impact laparoscopy, meaning low pressure PNP facilitated by deep NMB, could be a valuable addition to Enhanced Recovery After Surgery (ERAS) Protocols. The use of low pressure PNP may also reduce hypoxic injury and the release of DAMPs and thereby contributing to a better preservation of innate immune function which may help to reduce the risk of infectious complications. The participants will be randomly assigned to the experimental group 1: low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement or the experimental group 2: low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 12 mmHg IAP after trocar introduction for perfusion measurement, or control group 1: standard laparoscopy (standard pressure (12 mmHg) and moderate NMB (TOF 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement, or control group 2: standard laparoscopy (standard pressure (12 mmHg) and moderate NMB (TOF 1-2)); 12 mmHg IAP after trocar introduction for perfusion measurement. ICG injection will take place with starting pressure to quantify parietal peritoneum perfusion, and a parietal peritoneal biopsy will be taken. At the end of surgery, a second parietal peritoneum biopsy will be taken. NB: After introduction of the camera trocar, insufflation of carbon dioxide is titrated to an IAP of 8mmHg in group A and C, and 14 mmHg in group B and D. After placement of the last trocar the injection of ICG and video registration of peritoneum will take place, and a peritoneal biopsy will be taken. There after surgery will take place with an IAP of 14mmHg in the control groups (C and D), and an IAP of 8mmHg in the experimental groups (A and B). In the control groups (C and D) Pre- and postoperative a few questionnaires will be taken and blood withdrawals to evaluate the quality of recovery, and the immune response.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date March 7, 2022
Est. primary completion date December 9, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - - Age = 18 years - Undergoing elective robot assisted radical prostatectomy (RARP) - Obtained informed consent Exclusion Criteria: - Laparoscopic radical prostatectomy without robot assistance - Insufficient control of the Dutch language to read the patient information and to fill out de questionnaires - Neo-adjuvant chemotherapy - Chronic use of analgesics or psychotropic drugs - Use of NSAID's shorter than 5 days before surgery - Severe liver- or renal disease - Neuromuscular disease - Hyperthyroidism or thyroid adenomas - Deficiency of vitamin K dependent clotting factors or coagulopathy - Planned diagnostics or treatment with radioactive iodine < 1 week after surgery - Indication for rapid sequence induction - BMI >35kg/m2 - Known of suspected hypersensitivity to ICG, sodium iodide, iodine, rocuronium or sugammadex - Use of medication interfering with ICG absorption as listed in the summary of product characteristics (SPC); anticonvulsants, bisulphite compounds, haloperidol, heroin, meperidine, metamizol, methadone, morphium, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, cyclopropane, probencid

Study Design


Intervention

Other:
Low intra-abdominal pressure
8 mmHg
Deep neuromuscular blockade (NMB)
Deep NMB (PTC1-2)
Standard intra-abdominal pressure
14 mmHg
Moderate neuromuscular blockade (NMB)
Moderate NMB (TOF 1-2)

Locations

Country Name City State
Netherlands Canisius Wilhelmina ziekenhuis Nijmegen

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of recovery - 40 items questionnaire score (QoR-40) 40 points (minimum: extremely poor quality of recovery) to 200 points (maximum: excellent quality of recovery) at postoperative day 1
Primary Immune response represented by IL-6 IL-6 response upon whole blood LPS stimulation at postoperative day 1
Primary Immune response represented by IL-10 IL-10 response upon whole blood LPS stimulation at postoperative day 1
Primary Perfusion index of the parietal peritoneum calculated from the slope of ICG fluorescence intensity, and time to maximal intensity in seconds. (extracted from video registration). From ICG injection, up to 20 seconds
Secondary Quality of recovery - 40 items questionnaire score (QoR-40) 40 points (minimum: extremely poor quality of recovery) to 200 points (maximum: excellent quality of recovery) day 10 after surgery
Secondary Health status with short form survey (SF-36) The lower the score the more disability. The higher the score the less disability. day 10 and 3 months after surgery
Secondary Chronic pain with McGill pain questionnaire (MPQ) range from 0 (no pain) to 78 (severe pain) 3 months after surgery
Secondary Pain score with VAS pain scores with VAS 0 (no pain) to 10 (severe pain) During hospital stay up to 3 days
Secondary Analgesia use non-cumulative and cumulative opioid use per day in morphine equivalent During hospital stay up to 3 days
Secondary PONV With PONV impact scale score o (no PONV) to 6 (extreme PONV) During hospital stay up to 3 days
Secondary Hospital stay length of hospital stay in days from admission up to 3 days
Secondary Postoperative recovery time time to reach discharge criteria in days From day of surgery up to 3 days
Secondary Operating conditions surgical conditions with L-SRS 0 (extremely poor work field) to 5 (excellent work field) During operation for up to 8 hours
Secondary Complications postoperative complications scored by Clavien Dindo classification; grade 0 (no deviation from ideal) grade 5 (death of patient) Day of surgery untill 30days after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT06238557 - Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT05472935 - Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers N/A
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Active, not recruiting NCT04746664 - Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Active, not recruiting NCT05903638 - A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT03813420 - Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level N/A
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Terminated NCT03304184 - The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life Phase 3
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A